HALO(Halozyme Therapeutics, Inc.) · 财务报表

HALO(Halozyme Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$443.31M$660.12M$829.25M$1.02B$1.40B
毛利润$361.90M$520.81M$636.89M$855.91M$1.17B
营业利润$275.90M$267.53M$337.57M$551.48M$469.01M
净利润$402.71M$202.13M$281.59M$444.09M$316.89M
经营现金流$299.44M$240.11M$388.57M$479.06M$651.56M
自由现金流$297.98M$235.30M$373.28M$468.37M$644.59M
摊薄每股收益$2.74$1.44$2.10$3.43$2.56

Halozyme Therapeutics, Inc. HALO